We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-7.07%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$393M
AUM Growth
-$29.9M
Cap. Flow
+$15.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
52.55%
Holding
90
New
6
Increased
29
Reduced
20
Closed
8

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$5.71M
2
TELA icon
TELA Bio
TELA
+$4.05M
3
KROS icon
Keros Therapeutics
KROS
+$2.94M
4
BPMC
Blueprint Medicines
BPMC
+$2.56M
5
BCAX
Bicara Therapeutics
BCAX
+$2.2M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$3.48M
2
SLRN
ACELYRIN
SLRN
+$2.49M
3
AQST icon
Aquestive Therapeutics
AQST
+$2.13M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$1.3M
5
AXGN icon
Axogen
AXGN
+$1.26M

Sector Composition

Rank Sector Weight
1 Healthcare 86.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
26
Arcus Biosciences
RCUS
$3.48B
$3.79M 0.96%
254,217
-2,500
-1% -$40.8K
LKFT
27
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$3.58M 0.91%
130,175
– –
ALKS icon
28
Alkermes
ALKS
$8.32B
$3.47M 0.88%
120,700
– –
PODD icon
29
Insulet
PODD
$9.23B
$3.24M 0.82%
12,400
-3,500
-22% -$881K
ATXS
30
DELISTED
Astria Therapeutics
ATXS
$2.68M 0.68%
299,775
+45,610
+18% +$484K
IMVT icon
31
Immunovant
IMVT
$8.11B
$2.68M 0.68%
107,996
+56,000
+108% +$1.59M
ALLO icon
32
Allogene Therapeutics
ALLO
$673M
$2.64M 0.67%
1,240,118
+190,000
+18% +$469K
VKTX icon
33
Viking Therapeutics
VKTX
$3.91B
$2.6M 0.66%
64,516
-61,100
-49% -$3.48M
LXEO icon
34
Lexeo Therapeutics
LXEO
$349M
$2.59M 0.66%
393,083
+142,500
+57% +$1.12M
ARAY icon
35
Accuray
ARAY
$32.8M
$2.42M 0.62%
1,222,358
– –
KROS icon
36
Keros Therapeutics
KROS
$198M
$2.06M 0.52%
130,316
+56,562
+77% +$2.94M
INGN icon
37
Inogen
INGN
$187M
$1.91M 0.49%
208,790
– –
STOK icon
38
Stoke Therapeutics
STOK
$2.06B
$1.89M 0.48%
171,097
-36,330
-18% -$446K
BCAX
39
Bicara Therapeutics
BCAX
$1.7B
$1.84M 0.47%
+105,500
New +$2.2M
BWAY
40
Brainsway
BWAY
$602M
$1.82M 0.46%
386,416
-116,276
-23% -$566K
MLYS icon
41
Mineralys Therapeutics
MLYS
$2.37B
$1.8M 0.46%
146,500
– –
IMTX icon
42
Immatics
IMTX
$1.34B
$1.74M 0.44%
245,000
+100,000
+69% +$859K
ALEC icon
43
Alector
ALEC
$165M
$1.73M 0.44%
912,928
– –
IPSC icon
44
Century Therapeutics
IPSC
$353M
$1.72M 0.44%
1,704,232
– –
BCYC
45
Bicycle Therapeutics
BCYC
$278M
$1.69M 0.43%
120,799
-1,401
-1% -$30K
ITOS
46
DELISTED
iTeos Therapeutics
ITOS
$1.45M 0.37%
188,347
+26,763
+17% +$230K
LRMR icon
47
Larimar Therapeutics
LRMR
$426M
$1.44M 0.37%
371,434
-122,840
-25% -$811K
RGLS
48
DELISTED
Regulus Therapeutics
RGLS
$1.38M 0.35%
875,200
-20,000
-2% -$30.7K
AUTL
49
Autolus Therapeutics
AUTL
$506M
$1.38M 0.35%
586,667
+100,000
+21% +$338K
GOSS icon
50
Gossamer Bio
GOSS
$86.9M
$1.27M 0.32%
1,409,262
-10,000
-0.7% -$8.57K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, DAFNA Capital Management held 90 positions worth $393M, down 7.1% from $423M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $15.9M of net new capital in Q4 2024, opening 6 new positions and adding to 29 existing holdings. Its largest new stake was TELA Bio: 1,441,029 shares worth $4.35M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier.

On the sell side, the largest reduction was Viking Therapeutics, an estimated $3.48M trimmed.

  • DAFNA Capital Management's largest Q4 2024 buy was TELA Bio: 1,441,029 shares worth $4.35M.
  • DAFNA Capital Management added most to Revolution Medicines in Q4 2024, an estimated $5.71M increase.
  • DAFNA Capital Management's biggest Q4 2024 reduction was Viking Therapeutics, cutting an estimated $3.48M.
  • DAFNA Capital Management fully exited Nyxoah in Q4 2024, selling an estimated $1.03M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $393M portfolio in Q4 2024.
  • DAFNA Capital Management opened 6 new positions and closed 8 in Q4 2024.
  • DAFNA Capital Management's portfolio value fell 7.1% quarter-over-quarter to $393M.

Based on DAFNA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.